The Tax Cuts and Jobs Act of 2017 introduced significant changes to Section 174 of the Internal Revenue Code, affecting how businesses handle Research and Experimental (R&E) expenditures. Starting in 2022, these expenses must be capitalized and amortized over a specific period rather than being deducted in the year they are incurred. This blog post will guide you through the new rules and how to navigate them effectively.
From 1954 to 2021, Section 174 allowed businesses to deduct R&E expenditures immediately or amortize them over at least 60 months. The flexibility offered by the old rules enabled companies to optimize their tax liabilities based on their financial strategies.
Businesses must now accurately determine and capitalize their R&E expenditures. This requirement can lead to increased tax liability, particularly for companies not previously capitalizing these costs. For example, a company generating $500,000 in revenue and incurring $1,000,000 in R&D expenses would see a significant change in their taxable income under the new rules.
Since the Congress has failed to stop the new amortization rule to go in effect in 2022, there have been a few bills that were introduced since then; two bills at House (H.R. 7024, the Tax Relief for American Families and Workers Act of 2024, and H.R.2673 American Innovation and R&D Competitiveness Act of 2023) and one bill at Senate (S.966 American Innovation and Jobs Act). Of the three, the Tax Relief for American Families and Workers Act passed the House with bipartisan support in January 2024. However, the bill has not gained any cosponsors as of June 2024 even though it has been read twice in the Senate by March 2024, and it puts taxpayers and tax practitioners alike in an uncertain state of whether the bill will pass, if at all.
Do I need a Section 174 Study if I already have an R&D Tax Credit Study?
Yes, you do. The requirements for R&E expenditures under Section 174 are broader than those for R&D expenses under Section 41, which is used for calculating tax credits.
Can I skip the R&D tax credit and not report R&E expenditures for amortization?
No, you cannot. While the R&D tax credit is optional, amortizing R&E expenditures under Section 174 is mandatory starting from the 2022 tax year. Failing to report these expenditures can lead to accusations of tax evasion or fraud and increase your risk of IRS scrutiny.
How does this impact my tax liability?
It depends on your specific tax situation. If your company is profitable, the new amortization rule will increase your taxable income by 90% of the R&E expenditures in 2022, resulting in higher taxes. This increased tax liability will continue through 2023 to 2026 until the amortization catches up in 2027. However, for C Corporations with Net Operating Loss (NOL) carryovers and no expected profits, the new rule won't significantly impact net cash flow.
Could amortizing be more beneficial for me?
It could be, depending on your tax situation. For profitable C Corporations with NOL carryovers limited to 80% of taxable income, amortizing R&E expenditures might be more beneficial than deducting them in the year they are incurred. This approach can help convert NOL carryovers to R&E amortization for certain years.
Am I safe from an IRS audit if three years (statute of limitation) have passed since my tax filing?
Not necessarily. While the general statute of limitation for tax assessments is three years, it does not apply in cases of false or fraudulent returns or willful attempts to evade taxes (per IRC Section 6501(c)). If you intentionally fail to report R&D expenses to avoid amortizing them, it can be considered tax evasion, and the statute of limitation may not protect you.
TaxTaker provides specialized services to help businesses comply with the new Section 174 requirements:
The changes to Section 174 present new challenges for businesses engaged in research and development. By understanding the new rules and leveraging expert guidance, companies can navigate these complexities and optimize their tax strategies.
Sean Kim brings 10 years of experience and deep expertise in tax accounting to TaxTaker as the Sr. R&D Manager. Sean is a CPA with a Master's in Accounting from UNC Chapel Hill. Sean began his career at Deloitte, where he worked with a broad spectrum of clients across industries such as pharmaceuticals, manufacturing, and software. His entrepreneurial journey included owning a local business, showcasing his adeptness in navigating diverse financial landscapes and making impactful business decisions. Previously at LEAF Tax, Sean excelled as a meticulous Tax Manager, guiding clients through complex tax credit processes and offering crucial insights amidst evolving regulations. His unwavering commitment to exceptional client service and his diverse background make him an invaluable asset, perfectly aligned with TaxTaker's mission to empower businesses through expert tax consulting.